VNRXHIGH SIGNALRISK10-K

VNRX shows severe financial deterioration with a 66% cash decline, 57% increase in current liabilities, and worsening equity deficit of $34.2M despite 64% share dilution.

The massive 64% increase in outstanding shares (from 96.5M to 158.5M) combined with plummeting cash reserves suggests the company is burning through capital rapidly and relying heavily on equity dilutions to survive. The deteriorating working capital position and growing debt load indicate serious liquidity constraints that could threaten business continuity.

Comparing 2026-03-31 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

VNRX's financial position has deteriorated significantly, with cash declining 66% to just $1.1M while current liabilities surged 57% to $12.2M, creating a severe working capital deficit. Despite 40% revenue growth to $1.7M and reduced R&D spending, the company's equity deficit worsened to -$34.2M and total assets shrunk 27%, indicating the business is consuming more capital than it's generating. The 64% dilution in share count reveals heavy reliance on equity financing to fund operations, suggesting potential going concern issues.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
+187.4%
$111K$318K

Receivables surged 187.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Capital Expenditure
Cash Flow
-67.7%
$277K$90K

Capex reduced 67.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-65.8%
$3.3M$1.1M

Cash declined 65.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Liabilities
Balance Sheet
+57%
$7.8M$12.2M

Current liabilities surged 57% — significant near-term obligations; verify ability to meet short-term debt.

Current Assets
Balance Sheet
-49.2%
$4.1M$2.1M

Current assets declined 49.2% — monitor working capital adequacy and short-term liquidity.

Revenue
P&L
+40%
$1.2M$1.7M

Strong top-line growth of 40% — accelerating demand or successful expansion into new markets.

Total Debt
Balance Sheet
+39.4%
$4.8M$6.7M

Debt increased 39.4% — substantial leverage increase; assess whether deployed for growth or covering losses.

Stockholders Equity
Balance Sheet
-37.5%
-$24.9M-$34.2M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

R&D Expense
P&L
-30%
$14.4M$10.1M

R&D spending cut 30% — could signal cost discipline or concerning reduction in innovation investment.

Total Assets
Balance Sheet
-26.6%
$9.4M$6.9M

Total assets contracted 26.6% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-31
ADDED
As of March 26, 2026, there were 158,481,243 shares of the registrant s $0.001 par value common stock issued and outstanding.
Limited, Belgian Volition SRL, Volition Diagnostics UK Limited, Volition America, Inc.
and Volition Global Services SRL, as well as majority owned subsidiary Volition Veterinary Diagnostics Development LLC.
Nu.Q Cancer - from screening, diagnosis and staging, therapy decision, planning and treatment to monitoring response to treatment and disease progression with a particular focus on lung cancer.
We now have a team of over 75 dedicated employees, spanning a wide range of disciplines all united in our mission to improve outcomes for patients.
+7 more — sign up free →
REMOVED
As of March 20, 2025, there were 96,543,744 shares of the registrant s $0.001 par value common stock issued and outstanding.
Limited, Belgian Volition SRL, Volition Diagnostics UK Limited, Volition America, Inc, and Volition Global Services SRL, as well as majority owned subsidiary Volition Veterinary Diagnostics Development LLC.
Nu.Q Cancer - from screening, diagnosis and staging, therapy decision, planning and treatment to monitoring response to treatment and disease progression.
We now have a team of over 80 dedicated employees, spanning a wide range of disciplines; all united in our mission to improve outcomes for patients.
The Nu Q Vet Cancer Test is an accessible and affordable screening test to aid in the early detection of cancer in dogs.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →